IS2114B - Kínasólínafleiður til að meðhöndla æxli - Google Patents

Kínasólínafleiður til að meðhöndla æxli

Info

Publication number
IS2114B
IS2114B IS6647A IS6647A IS2114B IS 2114 B IS2114 B IS 2114B IS 6647 A IS6647 A IS 6647A IS 6647 A IS6647 A IS 6647A IS 2114 B IS2114 B IS 2114B
Authority
IS
Iceland
Prior art keywords
sup
quinazoline derivatives
treat tumors
containment
medicament
Prior art date
Application number
IS6647A
Other languages
English (en)
Other versions
IS6647A (is
Inventor
François André Hennequin Laurent
Ple Patrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27223613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2114(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6647A publication Critical patent/IS6647A/is
Publication of IS2114B publication Critical patent/IS2114B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS6647A 2000-06-06 2002-12-02 Kínasólínafleiður til að meðhöndla æxli IS2114B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00401581 2000-06-06
EP01400297 2001-02-07
EP01400565 2001-03-05
PCT/GB2001/002424 WO2001094341A1 (en) 2000-06-06 2001-06-01 Quinazoline derivatives for the treatment of tumours

Publications (2)

Publication Number Publication Date
IS6647A IS6647A (is) 2002-12-02
IS2114B true IS2114B (is) 2006-06-15

Family

ID=27223613

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6647A IS2114B (is) 2000-06-06 2002-12-02 Kínasólínafleiður til að meðhöndla æxli

Country Status (31)

Country Link
US (3) US7049438B2 (is)
EP (1) EP1292594B1 (is)
JP (1) JP3774438B2 (is)
KR (2) KR100807162B1 (is)
CN (1) CN100345844C (is)
AR (1) AR030937A1 (is)
AT (1) ATE275145T1 (is)
AU (2) AU2001260482B2 (is)
BG (1) BG65836B1 (is)
BR (1) BR0111335A (is)
CA (1) CA2407371C (is)
CO (1) CO5700751A2 (is)
CZ (1) CZ301987B6 (is)
DE (1) DE60105295T2 (is)
DK (1) DK1292594T3 (is)
EE (1) EE05481B1 (is)
ES (1) ES2225545T3 (is)
HU (1) HU229290B1 (is)
IL (2) IL152754A0 (is)
IS (1) IS2114B (is)
MX (1) MXPA02011765A (is)
MY (1) MY127369A (is)
NO (1) NO324838B1 (is)
NZ (1) NZ522204A (is)
PL (1) PL210852B1 (is)
PT (1) PT1292594E (is)
SI (1) SI1292594T1 (is)
SK (1) SK286748B6 (is)
TW (1) TWI288748B (is)
UA (1) UA73993C2 (is)
WO (1) WO2001094341A1 (is)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
UY27224A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
JP4307843B2 (ja) 2001-04-19 2009-08-05 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002365664A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1528925B1 (en) 2002-07-09 2009-04-22 Astrazeneca AB Quinazoline derivatives for use in the treatment of cancer
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
AU2003278383B2 (en) * 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
AU2003290279A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
UY29198A1 (es) * 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007063293A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
EP1957499A1 (en) 2005-12-02 2008-08-20 AstraZeneca AB 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008076883A2 (en) 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
WO2008077064A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Biomarker identifying the reactivation of stat3 after src inhibition
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US9256904B1 (en) 2008-08-14 2016-02-09 Experian Information Solutions, Inc. Multi-bureau credit file freeze and unfreeze
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
CN101723906B (zh) * 2008-10-10 2011-09-28 山西仁源堂药业有限公司 一种化合物、含该化合物的药物组合物及制备方法和用途
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
JP5785940B2 (ja) 2009-06-09 2015-09-30 アブラクシス バイオサイエンス， エルエルシー トリアジン誘導体類及びそれらの治療応用
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
IN2012DN03391A (is) 2009-11-18 2015-10-23 Astrazeneca Ab
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
CN103980337B (zh) 2010-01-15 2016-08-24 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
KR20120120307A (ko) 2010-01-19 2012-11-01 아스트라제네카 아베 피라진 유도체
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
CN103619865B (zh) 2011-02-02 2016-10-12 苏州润新生物科技有限公司 某些化学个体、组合物及方法
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
ES2725790T3 (es) 2011-08-26 2019-09-27 Neupharma Inc Algunas entidades químicas, composiciones, y métodos
CN115403531A (zh) 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US20140235573A1 (en) 2011-09-29 2014-08-21 The University Of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
CN104427873B (zh) 2012-04-29 2018-11-06 润新生物公司 某些化学个体、组合物及方法
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
CN104736533B (zh) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
DK3381917T3 (da) 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9937137B2 (en) 2013-03-15 2018-04-10 Neurocentria, Inc. Magnesium compositions and uses thereof for cancers
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10369152B2 (en) 2015-02-13 2019-08-06 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
USRE49850E1 (en) 2015-08-04 2024-02-27 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
US20210322415A1 (en) 2016-02-15 2021-10-21 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
KR101706346B1 (ko) 2016-06-09 2017-03-13 서동균 건축물의 외벽 마감재 고정장치
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10919896B2 (en) 2016-09-22 2021-02-16 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
JP7071392B2 (ja) 2016-12-05 2022-05-18 アプロス セラピューティクス， インコーポレイテッド 酸性基を含有するピリミジン化合物
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US11111245B2 (en) 2017-02-01 2021-09-07 Aucentra Therapeutics Pty Ltd Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
AU2017422200B2 (en) 2017-07-05 2022-11-24 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
WO2019034890A1 (en) 2017-08-18 2019-02-21 Cancer Research Technology Limited PYRROLO [2,3-B] PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
CN107987064A (zh) * 2017-12-30 2018-05-04 王兆举 一种治疗骨癌的药物塞卡替尼的制备方法
CN107814793A (zh) * 2017-12-30 2018-03-20 胡张艳 一种小分子Src酪氨酸激酶抑制剂塞卡替尼及其中间体的制备方法
EP3740484B1 (en) 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
AU2019218893B2 (en) 2018-02-08 2024-12-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CA3095371A1 (en) * 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
TW202003475A (zh) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 含酸性基團之嘧啶化合物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
EP3930715B1 (en) 2019-02-27 2024-05-08 Astrazeneca AB Saracatinib for use in the treatment of idiopathic pulmonary fibrosis
CA3133766A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
WO2020201773A1 (en) 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
WO2021037219A1 (zh) 2019-08-31 2021-03-04 上海奕拓医药科技有限责任公司 用于fgfr抑制剂的吡唑类衍生物及其制备方法
JP2022548690A (ja) 2019-09-20 2022-11-21 アイディアヤ バイオサイエンシーズ，インコーポレイティド Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
WO2022074391A1 (en) 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
KR102733257B1 (ko) 2021-05-17 2024-11-26 에이치케이이노엔 주식회사 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
CA3225500A1 (en) 2021-10-04 2023-04-13 Ulrich Luecking Parg inhibitory compounds
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
WO2023218201A1 (en) 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
KR20250073643A (ko) 2022-10-03 2025-05-27 포알엑스 테라퓨틱스 아게 Parg 억제 화합물
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
EP4612149A1 (en) 2022-11-02 2025-09-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
KR20250153866A (ko) 2023-03-10 2025-10-27 브레이크포인트 테라퓨틱스 게엠베하 Dna 중합효소 세타 억제제
EP4688159A1 (en) 2023-04-05 2026-02-11 FoRx Therapeutics AG Parg inhibitory compounds
GB202306601D0 (en) 2023-05-04 2023-06-21 Cancer Research Tech Ltd Inhibitor compounds
GB202307924D0 (en) 2023-05-26 2023-07-12 Neophore Ltd Inhibitor compounds
GB2631509A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631507A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025056923A1 (en) 2023-09-15 2025-03-20 Cambridge Enterprise Limited Combination therapy
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy
CN121889393A (zh) 2023-10-03 2026-04-17 福克斯治疗股份公司 Parg抑制化合物
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
GB202317368D0 (en) 2023-11-13 2023-12-27 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025104443A1 (en) 2023-11-14 2025-05-22 Storm Therapeutics Ltd Inhibitory compounds
WO2025114480A1 (en) 2023-11-28 2025-06-05 Forx Therapeutics Ag Wrn inhibitory compounds
AR134697A1 (es) 2023-12-18 2026-03-04 Ideaya Biosciences Inc Compuestos químicos y sus usos
GB202319864D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
GB202319863D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Movel compounds, compositions and therapeutics uses thereof
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2025191176A1 (en) 2024-03-14 2025-09-18 Forx Therapeutics Ag Wrn inhibitory compounds
NL2037411B1 (en) 2024-04-08 2025-10-31 Univ Leiden Protac compounds
GB202407738D0 (en) 2024-05-31 2024-07-17 Storm Therapeutics Ltd Inhibitory compounds
WO2025262192A1 (en) 2024-06-21 2025-12-26 Breakpoint Therapeutics Gmbh Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds
WO2026062066A1 (en) 2024-09-17 2026-03-26 Forx Therapeutics Ag Compounds inducing parg degradation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
RU2137762C1 (ru) 1994-02-23 1999-09-20 Пфайзер Инк. 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP4652569B2 (ja) * 1998-04-29 2011-03-16 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ−（３−エチニルフェニルアミノ）−６，７−ビス（２−メトキシエトキシ）−４−キナゾリンアミンメシレートの無水物及び一水和物
IL139641A0 (en) * 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
ATE232205T1 (de) 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
US7262201B1 (en) 1998-10-08 2007-08-28 Astrazeneca Ab Quinazoline derivatives
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
CA2361174C (en) 1999-02-27 2009-10-27 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6411963B1 (en) * 1999-07-09 2002-06-25 Junot Systems, Inc. External system interface method and system
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384282A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
DE60105295D1 (de) 2004-10-07
HUP0301046A3 (en) 2008-12-29
BR0111335A (pt) 2003-06-10
CZ20023961A3 (cs) 2003-03-12
IS6647A (is) 2002-12-02
EP1292594A1 (en) 2003-03-19
CA2407371C (en) 2009-10-20
ES2225545T3 (es) 2005-03-16
MXPA02011765A (es) 2003-04-10
US7049438B2 (en) 2006-05-23
WO2001094341A1 (en) 2001-12-13
US20060258642A1 (en) 2006-11-16
MY127369A (en) 2006-11-30
PL210852B1 (pl) 2012-03-30
BG65836B1 (bg) 2010-02-26
PT1292594E (pt) 2004-12-31
IL152754A0 (en) 2003-06-24
CN100345844C (zh) 2007-10-31
TWI288748B (en) 2007-10-21
SI1292594T1 (en) 2005-02-28
EE05481B1 (et) 2011-10-17
CO5700751A2 (es) 2006-11-30
EE200200673A (et) 2004-06-15
AU2001260482B2 (en) 2005-06-09
ATE275145T1 (de) 2004-09-15
JP3774438B2 (ja) 2006-05-17
UA73993C2 (uk) 2005-10-17
CN1434821A (zh) 2003-08-06
NO324838B1 (no) 2007-12-17
AU6048201A (en) 2001-12-17
SK286748B6 (sk) 2009-04-06
US7696214B2 (en) 2010-04-13
HK1053115A1 (en) 2003-10-10
US20100280042A1 (en) 2010-11-04
PL360745A1 (en) 2004-09-20
NO20025792D0 (no) 2002-12-02
IL152754A (en) 2010-05-31
SK17022002A3 (sk) 2003-05-02
HUP0301046A2 (hu) 2003-08-28
AR030937A1 (es) 2003-09-03
US20040214841A1 (en) 2004-10-28
BG107332A (bg) 2003-07-31
NO20025792L (no) 2002-12-02
KR20080015055A (ko) 2008-02-15
KR100807162B1 (ko) 2008-02-27
DK1292594T3 (da) 2004-12-06
WO2001094341A9 (en) 2003-04-17
JP2003535859A (ja) 2003-12-02
CA2407371A1 (en) 2001-12-13
NZ522204A (en) 2004-07-30
CZ301987B6 (cs) 2010-08-25
KR20030007859A (ko) 2003-01-23
HU229290B1 (en) 2013-10-28
DE60105295T2 (de) 2005-09-15
EP1292594B1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
IS6647A (is) Kínasólínafleiður til að meðhöndla æxli
ATE409185T1 (de) Chinazolin derivate
MY129809A (en) Quinazoline derivatives
GB0022438D0 (en) Organic Compounds
ATE353888T1 (de) Chinazolinderivate
PT1263724E (pt) Novos compostos
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
IS6658A (is) Ný efnasambönd
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
GB0112348D0 (en) Compounds
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
TW200510392A (en) Chemical compounds
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
ATE361287T1 (de) Neue indol-2-on derivate
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
TW200505452A (en) Chemical compounds
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
GB0012795D0 (en) Organic compounds
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
TH107320A (th) อนุพันธ์ควิแนโซลีน